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Filariasis
The ﬁ  larial nematodes Wuchereria 
bancrofti, Brugia spp., and Onchocerca 
volvulus are insect-borne parasites 
that cause lymphatic or cutaneous 
ﬁ  lariasis. Lymphangitis, hydrocele, 
and elephantiasis are pathologies that 
result from W. bancrofti and Brugia spp. 
infections. O. volvulus infections can 
present with severe skin pathologies 
(acute and chronic dermatitis, atrophy) 
and blindness (onchocerciasis, or river 
blindness). The nematodes infect more 
than 140 million people in 90 mostly 
tropical countries. An additional one 
billion people are at risk of contracting 
the diseases caused by these nematodes 
[1,2]. 
Current control efforts, both 
vector control and mass antiﬁ  larial 
chemotherapies, have shown initial 
success, but sustainability is uncertain. 
For example, vector control, used for 
onchocerciasis in west African savannah 
areas, has become too expensive and 
therefore been stopped. Current 
and planned elimination programs 
will rely on mass administration of 
antiﬁ  larial drugs that require annual 
administration for 5–10 years for 
lymphatic ﬁ  lariasis and more than 20 
years for onchocerciasis.
Control programs based on drug 
administration require long treatment 
durations because the adult female 
worms, which produce thousands of 
larvae daily, survive many years (over 14 
years for onchocerciasis) and are not 
killed by current drugs [1]. The success 
of such control programs, as shown by 
mathematical modeling, depends on a 
minimum of 60% of the people in an 
endemic area participating every year 
[3]. This is probably too optimistic 
an estimate, as a recent review of 
onchocerciasis therapy in regions that 
have had 10–12 years of ivermectin 
treatment still show infection levels 
of 2%–3%. These levels are enough 
to establish the infection within a few 
years after the end of annual drug 
administration [4]. Additionally, there 
is evidence that some geographic areas 
have worms with apparent resistance to 
ivermectin [5]. Therefore, it is essential 
that we ﬁ  nd new drugs that kill or 
sterilize adult worms.
Enter Wolbachia—Endosymbionts 
of Filarial Nematodes
For almost 30 years, it has been 
known that ﬁ  larial nematodes 
contain endosymbiotic bacteria. 
These endobacteria are found in 
the hypodermis of male and female 
worms, and in the oocytes, embryos, 
and larval stages (Figure 1). As in many 
animal ﬁ  larial species, endobacteria 
are present in the human ﬁ  lariae W. 
bancrofti, Brugia spp., and O. volvulus 
[1,6,7], but not in Loa loa [8,9]. 
Recently, these endosymbionts were 
classiﬁ  ed at the molecular level to be of 
the genus Wolbachia, a genus of bacteria 
that are common endosymbionts of 
arthropods. The next nearest relatives 
of Wolbachia are Rickettsia, Ehrlichia, 
Cowdria, and Anaplasma [10]. 
Studies of the effect of antirickettsials 
such as tetracycline and rifampicin 
in animals infected with ﬁ  larial 
nematodes have shown, using 
immunohistochemistry, that these 
drugs deplete the Wolbachia from 
the worms. After the Wolbachia are 
depleted, the worms develop a distinct 
phenotype. Monitoring the microﬁ  laria 
(Mf) levels in the blood showed that 
the number of Mf in the treated 
animals was lower than the number 
in the control groups, and that the 
number of Mf in the treated group 
neared zero with time. Examination 
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Figure 1. Cross-Section of a Female Worm 
from an Extirpated Nodule from a Patient with 
Onchocerciasis
Wolbachia, endosymbiotic bacteria of 
ﬁ  larial nematodes important for embryo 
development, are targets for antiﬁ  larial 
treatment. The endobacteria cause 
inﬂ  ammation and contribute to the 
pathology of lymphatic ﬁ  lariasis and 
onchocerciasis. The bacteria here were 
stained with antibodies against Yersinia 
Hsp60. The bacteria are located in the 
hypodermis and oocytes of the worm 
(arrows). h, hypodermis; i, intestine; m, 
muscle; u, uterine tube. 
(Photo: D.W. Büttner, Bernhard 
Nocht Institute for Tropical Medicine, 
Hamburg, Germany)PLoS Medicine  |  www.plosmedicine.org 0290
of the adult worms showed that 
embryogenesis was blocked and the 
uteri contained degenerated embryos 
[1]. A study done in cattle infected with 
O. ochengi even showed killing of adult 
worms [11].
The success of antibiotic treatment 
against animal ﬁ  lariae has been 
extended to human ﬁ  larial infections. 
Trials of doxycycline have been 
completed for populations infected 
with O. volvulus and W. bancrofti. For 
both species, larval levels were zero 
or near zero after treatment [6,12]. 
Examination of worms from extirpated 
nodules of patients with onchocerciasis 
showed that, as in the animal studies, 
depletion of Wolbachia led to a block 
in embryogenesis that appears to be 
permanent [2]. Most recently, there 
has been evidence for the killing 
of adult W. bancrofti by doxycycline 
therapy [13].
Wolbachia stimulate inﬂ  ammatory 
responses via Toll-like receptor (TLR) 
2 and TLR4 [14], pattern recognition 
receptors that recognize a variety of 
bacterial molecules [15]. Working with 
a mouse model of O. volvulus–induced 
corneal inﬂ  ammation (keratitis), it has 
been shown that Wolbachia antigens 
presented via TLR4 are required for 
the development of pathology [16]. 
Wolbachia have also been associated 
with adverse reactions seen in infected 
patients after antiﬁ  larial therapy. 
Recent studies supporting a role for 
Wolbachia in adverse reactions after 
antiﬁ  larial treatment have shown that 
doxycycline given before ivermectin 
reduced Wolbachia loads as well as 
the number and severity of adverse 
reactions in patients with lymphatic 
ﬁ  lariasis ([17]; J. Turner, S. Mand, 
A. Y. Debrah, J. Muehlfeld J, K. M. 
Pfarr, et al., unpublished data). Thus, 
doxycycline fulﬁ  lls the role for a new 
antiﬁ  larial therapy in that it produces 
sterility in lymphatic ﬁ  lariasis and 
onchocerciasis, kills adult worms in 
lymphatic ﬁ  lariasis, and prevents or 
lessens adverse reactions due to the 
rapid killing of Mf by microﬁ  laricidal 
drugs. However, the treatment time 
of four weeks is still longer than that 
desired for new antiﬁ  larial therapies. 
Wolbachia are ideal targets for 
antiﬁ  larial drugs that have the same 
effect as doxycycline, but that work in a 
shorter interval. Potential drug targets 
may be found by analyzing the genome 
of Wolbachia.
Sequencing the Wolbachia 
Genome
As part of the effort to ﬁ  nd 
antiwolbachial drugs that act in less 
time than the current four-week regime 
for doxycycline, a consortium was 
established to sequence the genomes 
of the Wolbachia species that inhabit 
human ﬁ  larial nematodes. In the April 
2005 issue of PLoS Biology, Foster and 
colleagues report on the completion of 
the sequencing and annotation of the 
genome from the Wolbachia of Brugia 
malayi (wBm) (Figure 2) [18]. This is 
the ﬁ  rst complete Wolbachia genome 
from a ﬁ  larial nematode. The authors 
compare the wBm genome to the ﬁ  rst 
sequenced genome of the Wolbachia of 
Drosophila melanogaster (wMel), which 
is strictly parasitic, and the genomes of 
other endosymbiotic bacteria, pointing 
out potential metabolites that wBm may 
supply to the nematode.
Features of the Genome 
and Metabolites that wBm May 
Provide to Its Host
The genome of wBm is 1.1 million 
nucleotides, smaller than wMel and 
Rickettsia prowazekii, but larger than 
that of Mycobacterium. The reduced 
genome size is indicative of long-term 
symbiosis, and reﬂ  ects the loss of all 
genes necessary to make all but one 
amino acid, genes needed to infect new 
DOI: 10.1371/journal.pmed.0020110.g002
Figure 2. Annotation of the Complete Wolbachia Genome 
(Figure from [18])
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hosts, and genes needed to evade the 
host immune system. Also lacking from 
the wBm genome are several genes 
needed for DNA repair and genes 
required for RNA modiﬁ  cation. Many 
of these genes have also been lost from 
other endosymbiotic bacteria. wBm 
cannot synthesize lipopolysaccharide, 
a component of the cell membrane 
in most bacteria. This is astounding 
because, as noted above, Wolbachia 
stimulate an inﬂ  ammatory reaction 
via TLR4. Endobacteria antigens 
presented via TLR4 are also responsible 
for adverse reactions after antiﬁ  larial 
treatment [17], and for pathology 
in onchocerciasis [16]. wBm lack 
the genes necessary to cross-link and 
degrade the carbohydrate backbone 
of peptidoglycan. The Wolbachia 
peptidoglycan structure resembles 
the peptidoglycan-derived cytotoxins 
produced by Neisseria gonorrhoeae and 
Bordetella pertussis, which are made 
up of muramyl peptides [19]. These 
muramyl peptides are known to 
stimulate an inﬂ  ammatory response 
and pathology via TLR2.
However, to understand the 
Wolbachia–ﬁ  laria endosymbiosis, it is not 
only important what wBm has lost from 
the genome during its long symbiosis 
with B. malayi, but also what has been 
kept. The endobacteria have retained 
all of the genes necessary for the 
synthesis of the co-factors riboﬂ  avin, 
ﬂ  avin adenine dinucleotide, and 
heme. The genome also contains the 
genes necessary to make glutathione, 
although it lacks the genes needed for 
glutathione-mediated methylglyoxal 
detoxiﬁ  cation [20], which is the most 
common reason intracellular bacteria 
need glutathione. Finally, in contrast 
to most endosymbiotic bacteria, wBm 
have retained the genes necessary to 
make all nucleotides. 
As the wBm genome has the genes 
for a type IV secretion system, used 
by intracellular bacteria for exporting 
molecules to nonbacterial (e.g., host) 
cells, the above described metabolites 
could be supplied to the nematode 
host by Wolbachia. To date, there is no 
evidence of genes for riboﬂ  avin and 
heme synthesis in the B. malayi genome 
[21]. Heme from Wolbachia could be 
vital to worm embryogenesis, as there is 
evidence that molting and reproduction 
are controlled by ecdysteroid-like 
homones [22], whose synthesis requires 
heme. Depletion of Wolbachia would 
therefore halt production of these 
hormones and block embryogenesis. 
Wolbachia could be a source of 
glutathione which, aside from its role 
in the detoxiﬁ  cation of methylglyoxal, 
is required for protection against 
oxidative stress from oxygen-reactive 
species secreted by mammalian immune 
cells [23]. Finally, Wolbachia may be an 
essential source of nucleotides during 
embryogenesis. Wolbachia as a source 
of the above metabolites would explain 
the block in embryogenesis and the 
sterility seen in worms after depletion of 
the endobacteria.
Conclusion
The completion of the wBm genome 
offers a wealth of information for both 
basic and applied science. With the 
completion of this genome, one can 
now compare close relatives that infect 
different hosts and have different 
symbiotic lifestyles, i.e., parasitic versus 
mutualistic. Such a comparison of 
the differences could help to deﬁ  ne 
genes necessary for invading host cells. 
Examining the genome of wBm will 
help us understand the molecular basis 
for the endosymbiosis between ﬁ  larial 
nematodes and Wolbachia. Researchers 
now know which metabolites the 
endobacteria require from the 
nematode host and which might be 
provided by Wolbachia to the nematode. 
This is exciting because it opens up the 
possibility to ﬁ  nd and test drugs already 
registered for use in humans that might 
inhibit key biochemical pathways in 
the Wolbachia—and lead to sterility or 
killing of the adult worms in shorter 
treatment times—and that could be 
given to all infected persons. Given the 
huge challenges that still lie ahead for 
the programs to eliminate ﬁ  lariasis, 
such a need has been and will be 
repeatedly stated. The sequencing and 
annotation of the wBm genome will 
aid researchers in fulﬁ  lling this goal by 
focusing research on those biochemical 
events that are essential to the 
mutualistic symbiosis between ﬁ  larial 
nematodes and their Wolbachia.  
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